tbuckley/cabot-search huggingface dataset:
Gene expressions of VEGF and Survivin as molecular markers of lymph node involvement in patients with locally advanced rectal cancer
Authors: D. Yang, S. Schneider, K. D. Danenberg, P. V. Danenberg, H.-J. Lenz
Journal: Journal of Clinical Oncology (2004)

9526 Background: Patients diagnosed with locally advanced rectal cancer usually receive surgical resection and adjuvant radio-chemotherapy for their disease. Lymph node involvement is an important clinical prognostic factor affecting type of surgery, recurrence, and survival. Few studies have explored molecular markers associated with lymph node involvement. Methods: Tissue was obtained from 73 patients with locally advanced rectal cancer (UICC stage II and III) who were treated with adjuvant radio-chemotherapy. We assessed mRNA levels of genes involved in angiogenesis (VEGF, COX-2), apoptosis (Survivin), tumor growth and epidermal growth factor (EGFR), DNA repair (ERCC1, RAD51), and the 5-FU pathway (TS, DPD) from paraffin-embedded samples using laser-capture-microdissection methods. In tumor and adjacent normal tissue, univariate and multivariate (controlling for T stage) logistic regression models were used to examine the association between the expression level of each gene and lymph node involvement. Results: There were 25 women and 48 men with a median age of 52 (range 25–79) years. Thirty-five patients had no involvement of regional lymph nodes (pN0), 38 had lymph node metastases (pN+). Twenty-four of the 35 pN0 patients and 27 of the 38 pN+ patients were stage T3. The higher gene expression level of VEGF and Survivin in tumor tissue were statistically significantly associated with the higher likelihood of lymph node involvement compared with lower expression level when adjusting for T-stage (OR=3.16 and 2.24 for VEGF and Survivin, respectively, p <.05). The patients with higher expression level of DPD in tumor tissue or EGFR in adjacent normal tissue were at higher risk of lymph node involvement compared with those with the lower expression level (p <.10). Conclusions: Gene expressions of VEGF, SURVIVIN, DPD, and EGFR may be associated with lymph node involvement in patients with resected rectal cancer. Further studies of those gene expression levels and lymph node involvement are warranted to better characterize the associations. No significant financial relationships to disclose.
Comprehensive analysis of <i>UGT1A</i> polymorphisms predictive for pharmacokinetics and treatment outcome in non-small cell lung cancer patients treated with irinotecan and cisplatin
Authors: J. Han, H. Lim, S. Lee, D. Lee, H. Kim, J. Lee
Journal: Journal of Clinical Oncology (2006)

13121 Purpose: To determine whether UGT1A1, UGT1A7, and UGT1A9 polymorphisms affect pharmacokinetics (PK) of irinotecan and treatment outcome of Korean patients with advanced non-small cell lung cancer (NSCLC). Methods: Eighty-one patients with advanced NSCLC were treated with irinotecan and cisplatin chemotherapy. Genomic DNA was extracted from peripheral blood and genotyped using direct sequencing. We analyzed the association of UGT1A genotypes with irinotecan PK and clinical outcomes. Results: In genotype-PK association analysis, UGT1A1*6/*6 (n = 6), UGT1A7*3/*3 (n = 6) and UGT1A9–118(dT) 9/9 (n = 11) were associated with significantly lower AUC SN-38G /AUC SN-38 ratio (P = 0.002, 0.009and 0.001, respectively). In linkage disequilibrium (LD) analysis, the UGT1A7 variants were highly linked with UGT1A1*6 (D` = 0.85, r 2 = 0.63) and UGT1A9*22 (D` = 0.95, r 2 = 0.88), which was substantiated in haplotype analysis. Patients with UGT1A1*6/*6 had lower tumor response and higher incidence of severe neutropenia. UGT1A9–118(dT) 9/9 also showed a trend for high incidence of severe diarrhea, but not tumor response. In survival analysis, patients with UGT1A1*6/*6 had significantly shorter progression-free survival (P = 0.001) and overall survival (P = 0.017). Conclusions: These findings suggest that UGT1A1*6 and UGT1A9*22 genotypes may be important for SN-38 glucuronidation and associated with irinotecan-related severe toxicity. Specifically, UGT1A1*6 might be useful for predicting tumor response and survival outcome of Korean patients with NSCLC treated with irinotecan-based chemotherapy. (Supported in part by NCC Grant 0210130 and 0510080 from National Cancer Center, Korea). No significant financial relationships to disclose.
EFFECT OF CHANGING STRAIN SOFTWARE VERSIONS ON LONGITUDINAL ASSESSMENT OF LV FUNCTION
Authors: Tomoko Negishi, Kazuaki Negishi, Koji Kurosawa, Krasimira Hristova, Julie Lemieux, Svend Aakhus, Martin Penicka, Bogdan Popescu, Dragos Vinereanu, Goo-Yeong Cho, Paaladinesh Thavendiranathan, Thomas Marwick
Journal: Journal of the American College of Cardiology (2017)
Dexamethasone Reduces Incidence of Relapse and Improves Overall Survival in Hyperleucocytic Acute Myeloid Leukemia
Authors: Christian Récher, Sarah Bertoli, Muriel Picard, Emilie Bérard, Clément Larrue, Suzanne Tavitian, Francois Vergez, Edwige Yon, Jean Ruiz, Eric Delabesse, Isabelle Luquet, Laetitia Linares, Martin Carroll, Audrey Sarry, Françoise Huguet, Jean-Emmanuel Sarry
Journal: Blood (2016)
Multiple primary tumors in patients with carcinosarcoma of bladder: A coincidence or an etiological association? A study of 221 carcinosarcoma of bladder cases
Authors: J. Wang, F. Wang
Journal: Journal of Clinical Oncology (2009)

e16138 Background: Carcinosarcoma of the bladder are rare; As a result, few studies of carcinosarcoma of the bladder have included sufficient number of patients to define their natural history and to determine the factors that impact survival. The objective of this study was to examine the epidemiology, natural history, and prognostic factors that affect the survival for carcinosarcoma of the bladder by using population-based registries. Methods: The Surveillance, Epidemiology, and End Results (SEER) Program database (1973–2004) was used to identify cases of carcinosarcoma of the bladder by tumor site and histology codes. The association between clinical and demographic characteristics and survival of carcinosarcoma of the bladder was examined. Results: A total of 221 cases of histology confirmed carcinosarcoma of the bladder were identified, this account for approximately 0.11% of primary bladder tumors during same period. By using linked population files, we calculated the incidence of carcinosarcoma of the bladder as a rate 0.22 per 100,000 per year, age-adjusted to year 2000 U.S. standard population. Median age of all patients were 75 years (range 41–96). In about 40% of study population, more than one or multiple primary were also indentified. Majority of (212, 95.9 %) patients received cancer directed surgery. For survival analyses, we excluded the cases that were identified at autopsy or on the basis of death certificates only and the patients have more than one primary. Total 132 patients were included in survival analysis. The median overall survival for all cases was 9 months (range 6–12 months). In multivariate analysis, only tumor stage was found to be significant prognostic factors for disease-specific survival. Conclusions: Carcinosarcoma of the bladder are rare tumors that are challenging, the survival is poor even in patients underwent surgical resection. Better therapy is needed to improve patient's outcome. A significant fraction of carcinosarcoma patients are actually affected by multiple primary tumors, the potential association between carcinosarcoma and other neoplasms remain to be investigated. No significant financial relationships to disclose.
Serum beta2-Microglobulin before Transplantation Is an Independent Predictor of Outcome in Patients with Multiple Myeloma Treated Using Autologous HCT; a Single Centre Multivariate Analysis in a Series of 81 Patients.
Authors: Beata M. Stella-Holowiecka, Tomasz Czerw, Aleksandra M. Holowiecka-Goral, Sebastian Giebel, Jerzy Wojnar, Jerzy Holowiecki
Journal: Blood (2005)
Autologous Stem Cell Transplant (ASCT) in HIV-1 Positive (HIV+) Hodgkin Lymphoma (HL) Patients in the HAART Era: Are Clinical Results Comparable to Those in HIV-1 Negative (HIV−) HL Patients?.
Authors: Pascual Balsalobre, David Serrano, Rafael Carrion, Javier Anguita, Pilar Miralles, Juan Berenguer, Ismael Buño, Alfonso Gomez-Pineda, Rosario Varela, Javier Loscertales, Lourdes Escoda, Josep-Maria Ribera, Jose L. Diez-Martin
Journal: Blood (2006)
EXTRACORPOREAL CIRCULATORY LIFE SUPPORT IS SUPERIOR TO INTRA-AORTIC BALLOON PUMP IN ACUTE CORONARY SYNDROME AND CARDIOGENIC SHOCK
Authors: Mariusz Zadura, Frank Szigat, Barnaba Hejazin, Ronald Bittner, Peter Szigat, Claudia Bischoff, Wolfgang Motz
Journal: Journal of the American College of Cardiology (2017)
CLINICAL OUTCOMES OF THE TREATMENT OF COCAINE INDUCED CHEST PAIN WITH BETA BLOCKERS: A META-ANALYSIS
Authors: Carlos A. Gongora, Seyedhamed Hosseinidehkordi, Alejandro Lemor, Chirag Bavishi, Abel Casso Dominguez, Alejandro Zulbaran, Karomibal Mejia, Farit Gholitabar, Shawn Lee, Shilpkumar Arora, Hafeez Hassan, Edgar Argulian
Journal: Journal of the American College of Cardiology (2017)
RVD + ASCT + Lenalidomide Maintenance Benefits Patients without High-Risk Cytogenetics and Results in Recovery of the Normal Plasma Cell Composition in Bone Marrow
Authors: Raija Silvennoinen, Pekka Anttila, Marjaana Säily, Tuija Lundan, Jouni Heiskanen, Timo Siitonen, Sakari Kakko, Mervi Putkonen, Hanna Ollikainen, Venla Terävä, Anu Partanen, Kirsi Launonen, Anu Räsänen, Anu Sikiö, Merja Suominen, Piotr Bazia, Kristiina Kananen, Juha Lievonen, Tuomas Selander, Imre Västrik, Tarja-Terttu Pelliniemi, Kimmo Porkka, Kari Remes, Esa Jantunen
Journal: Blood (2016)
Radiation Exposure and Vascular Access in Acute Coronary Syndromes
Authors: Alessandro Sciahbasi, Enrico Frigoli, Alessandro Sarandrea, Martina Rothenbühler, Paolo Calabrò, Alessandro Lupi, Francesco Tomassini, Bernardo Cortese, Stefano Rigattieri, Enrico Cerrato, Dennis Zavalloni, Antonio Zingarelli, Paolo Calabria, Paolo Rubartelli, Gennaro Sardella, Matteo Tebaldi, Stephan Windecker, Peter Jüni, Dik Heg, Marco Valgimigli
Journal: Journal of the American College of Cardiology (2017)
Impact of In Vivo T-Cell Depletion on Outcome Following Reduced Intensity Transplantation for Hodgkin Lymphoma: Comparison between 2 Prospective Studies.
Authors: K. S. Peggs, A. Sureda, A. Hunter, M. D. Caballero, J. Cavet, A. Urbano-Ispizua, A. Parker, J. M. Ribera, P. Mahendra, M. A. Canales, D. Milligan, J. C. Hernandez-Boluda, E. C. Morris, I. Alvarez, A. H. Goldstone, D. C. Linch, J. Sierra, S. Mackinnon
Journal: Blood (2004)
Long-term bosutinib (BOS) in patients (pt) with chronic phase (CP) chronic myeloid leukemia (CML) after prior imatinib (IM) failure.
Authors: Jeffrey Howard Lipton, Jorge E. Cortes, Hanna Jean Khoury, Hagop M. Kantarjian, Dong-Wook Kim, Philippe Schafhausen, Mirjana Zeremski, Nathalie Bardy-Bouxin, Mark Shapiro, Eric Leip, Carlo Gambacorti-Passerini, Tim H. Brümmendorf
Journal: Journal of Clinical Oncology (2015)

7076 Background: BOS is a Src/Abl tyrosine kinase inhibitor for adults with Ph+ CML resistant/intolerant to prior therapy. We assess long-term efficacy/tolerability of BOS after ≥5 y vs ≥2 y follow-up from last enrolled pt. Methods: Data were from an ongoing phase 1/2 study in CP CML pts on 2nd-line BOS (500 mg/d start dose) after IM failure (n = 284). Results: 41% of pts remained on BOS at 5 y vs 54% at 2 y (1 y = 48 wk); 60% and 50% had newly attained or maintained baseline major cytogenetic response (MCyR) or complete cytogenetic response (CCyR) (most in ≤2 y). Kaplan-Meier (KM) probability of maintaining MCyR or CCyR in responders was similar at 5 y (71%, 71%) and 2 y (76%, 79%); 6 and 7 pts lost response > 2 y. Cumulative incidence of on-treatment transformation to AP/BP CML at 5 y was 4%; 55% discontinued without transformation < y5. 1/153 pts on-treatment > 2 y transformed to AP in y3–5. KM overall survival was 84% at 5 y vs 91% at 2 y (40% censored < y5). Median treatment duration was 25.6 (range 0.2–94.9) mo; follow-up: 51.4 (0.6–96.3) mo. 37 pts discontinued BOS y3-5 (vs 131 ≤2 y), mostly for disease progression (n = 11), AE (n = 7, y3: coronary artery disease, scleroderma, renal failure; y4: ascites and serositis [same pt], blood creatinine increased, pulmonary hypertension; y5: thrombocytopenia), and unsatisfactory efficacy (n = 7). Common newly occurring AEs (in > 5 pts) in y3 were cough (n = 7), blood creatinine increased (n = 7), pyrexia (n = 6), and blood creatine phosphokinase increased (n = 6); y4: blood creatinine increased (n = 6), pleural effusion (n = 6); y5, none in > 5 pts. Newly occurring AEs of interest (Table) were most common in y1–2; vascular AEs > y2 were primarily hypertension (y3, n = 5; y4, n = 3; y5, n = 2). 4 on-treatment deaths occurred y3–5, none BOS-related. Conclusions: BOS showed durable efficacy and manageable toxicity; a large proportion of CP CML pts with prior IM failure remained successfully treated at 5 y. Clinical trial information: NCT00261846. Newly Occurring AEs* n (%) Y1 n = 284 Y2 n = 189 Y3 n = 148 Y4 n = 130 Y5 n = 124 Diarrhea 239 (84) 3 (2) 0 1 (1) 0 Cardiac 23 (8) 7 (4) 8 (5) 7 (5) 4 (3) Vascular 11 (4) 8 (4) 5 (3) 4 (3) 5 (4) Renal 14 (5) 4 (2) 8 (5) 7 (5) 5 (4) *Not experienced by same pt previously (denominator = pts on treatment each y; 1 y = 52 wk)
The Rate of Cytomegalovirus Infection and Disease in Correlation with the Type of Hematopoietic Stem Cell Transplantation in the Era of Preemptive Antiviral Therapy
Authors: Benjamin Gesundheit, Reuven Or, Einat Budowski, Michael Y. Shapira, Igor B. Resnick, Simcha Samuel, Liliane Dray, Orit Kaplan, Dana Wolf
Journal: Blood (2008)
IMPLICATIONS OF WORSENING RIGHT VENTRICULAR FUNCTION FOLLOWING TRANSCATHETER OR SURGICAL AORTIC VALVE REPLACEMENT: INSIGHTS FROM PARTNER2A
Authors: Paul Cremer, L. Leonardo Rodriguez, Yiran Zhang, Maria Alu, Brian Lindman, Alan Zajarias, Rebecca Hahn, Stamatios Lerakis, S. Chris Malaisrie, Pamela Douglas, Philippe Pibarot, Lars Svensson, Martin Leon, Wael Jaber
Journal: Journal of the American College of Cardiology (2017)
RIGHT VENTRICULAR CONTRACTILE RESERVE IS REDUCED IN CHILDREN AND ADOLESCENTS WITH TETRALOGY OF FALLOT: A STRESS ECHOCARDIOGRAPHIC STUDY
Authors: Shivani M. Bhatt, Elizabeth Goldmuntz, Okan Elci, Michael McBride, Stephen Paridon, Laura Mercer-Rosa
Journal: Journal of the American College of Cardiology (2017)
Transdifferentiation of Bone Marrow Pro-B Cells into Bone-Resorbing Osteoclasts- an Unexpected Role for Erythropoietin
Authors: Naamit Deshet-Unger, Sahar Hiram-Bab, Nathalie Ben-Califa, Dafna Gilboa, Tamar Liron, Kolomansky Albert, Howard S Oster, Moshe Mittelman, Yankel Gabet, Drorit Neumann
Journal: Blood (2016)
Bortezomib Consolidation after Nonmyeloablative Allogeneic Stem Cell Transplantation Leads to a High Incidence of Immunophenotypic Complete Response in Young and/or High-Risk Multiple Myeloma Patients
Authors: Richard LeBlanc, Imran Ahmad, Rafik Terra, Séverine Landais, Michael Sebag, Emilie Lemieux-Blanchard, Nadia M. Bambace, Lea Bernard, Sandra Cohen, Jean-Sebastien Delisle, Thomas Kiss, Silvy Lachance, Denis-Claude Roy, Guy Sauvageau, Jean Roy
Journal: Blood (2016)
Re-evaluation of the role of lumen-apposing metal stents (LAMS) for pancreatic ﬂuid collection drainage
Authors: Huiyun Zhu, Han Lin, Zhendong Jin, Yiqi Du
Journal: Gut (2017)

We read with great interest the recent endoscopy news reported by Bang et al ,1 discussing the lumen-apposing metal stents (LAMS) for pancreatic fluid collection (PFC) drainage. Patients with walled-off necrosis (WON) treated by using LAMS in their centre occurred a 50% (6/12) rate of adverse events including delayed bleeding (3/12), buried stent syndrome (2/12) and biliary stricture (1/12), which is higher than we expected on our experiences.

As the authors reported all three patients presented with severe bleeding were confirmed with pseudoaneurysms. But another data from Sharaiha et al 2 showed that LAMS method was safe for PFC. In 124 patients with WON underwent endoscopic …
DESIGNING TAILORED HEALTH MESSAGING TO ENHANCE PATIENT-CENTERED CARE IN NON-VALVULAR ATRIAL FIBRILLATION
Authors: Amelia Roebuck, Maria Carpenter, Carly Daley, Romisa Rohani Ghahari, Shauna Wagner, Ryan Ahmed, Tammy Toscos, Michael Mirro
Journal: Journal of the American College of Cardiology (2017)
Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC)
Authors: A. Duffy, M. Capanu, G. K. Abou-Alfa, D. Huitzel, P. Williams, W. Jarnagin, Y. Fong, D. P. Kelsen, E. M. O’Reilly
Journal: Journal of Clinical Oncology (2007)

4648 Background: The incidence of GBC in the US is 1.2/ 100,000. Given the dearth of phase III data on the use of adjuvant therapy, institutional review can provide a justification for future studies. This report examines the patterns of presentation, treatment and survival of a large cohort of patients with GBC evaluated at MSKCC over a 10-year period. Methods: A retrospective analysis of patients referred to MSKCC with a diagnosis of GBC between 1/1995 and 12/ 2005 was performed. Patients were identified from the MSKCC cancer registry. Information extracted included, demographics, stage, surgical management, pathology, adjuvant and palliative therapy, date of relapse, death or last follow-up. Date of diagnosis was defined as date of surgery or biopsy. Univariate analysis of survival times and log rank test were employed. Results: 435 GBC cases were identified. 285 (65.5%) females,150 (34.5%) males. Median age 67 years (range 28–100). Pathology: 88% adeno, 4% squamous, 3% neuroendocrine, 2% sarcoma. 36.6% presented as AJCC Stage IV. 47% were discovered incidentally at laparoscopic cholecystectomy (LC). 136 of these were re-explored, of whom 100 (73.5%) had residual disease. Of those who underwent curative resections, 8 received adjuvant chemotherapy, 2 adjuvant radiotherapy and 17 combined chemoradiation. Median OS for the cohort was 9.11 months(m). The median survival(MS) for those presenting with stage IV disease was 4.5 m (95% CI 3.8–6.1) compared to 12.9 m (95% CI 11.7–15.8 m) for those with stage IA-III disease. MS was better for those discovered incidentally at LC (15.7 m,p&lt;.001). For those who underwent re-exploration, MS was 13.9 m if residual disease was present, and 68 m if no residual disease. The MS for those who received adjuvant therapy was 23.4 m. Conclusions: GBC is commonly diagnosed incidentally (47%) at LC. Re- exploration reveals a high incidence of residual disesase (74%). MS is better for patients diagnosed incidentally and those without evidence of disease on re-exploration. Overall prognosis is poor. Although the number of patients was small, adjuvant therapy appeared to confer a survival benefit. Prospective randomized trials of adjuvant therapy are needed in this disease. No significant financial relationships to disclose.
Brain Ischemia Suppresses Immunity in the Periphery and Brain via Different Neurogenic Innervations
Authors: Qiang Liu, Wei-Na Jin, Yaou Liu, Kaibin Shi, Haoran Sun, Fang Zhang, Chao Zhang, Rayna J. Gonzales, Kevin N. Sheth, Antonio La Cava, Fu-Dong Shi
Journal: Immunity (2017)
Impact of Lifelong Exercise Training Dose on Ventricular-Arterial Coupling
Authors: Michinari Hieda, Erin Howden, Shigeki Shibata, Naoki Fujimoto, Paul S. Bhella, Jeffrey L. Hastings, Takashi Tarumi, Satyam Sarma, Qi Fu, Rong Zhang, Benjamin D. Levine
Journal: Circulation (2018)

Background: The dynamic Starling mechanism, as assessed by beat-by-beat changes in stroke volume and left ventricular end-diastolic pressure, reflects ventricular-arterial coupling. It deteriorates with age, and is preserved in highly trained masters athletes. Currently, it remains unclear how much exercise over a lifetime is necessary to preserve efficient ventricular-arterial coupling. The purpose of this study was to assess the dose-dependent relationship between lifelong exercise training and the dynamic Starling mechanism in healthy seniors. Methods: One hundred two seniors were recruited and stratified into 4 groups based on 25 years of exercise training history: sedentary subjects (n=27, &lt;2 sessions/week), casual exercisers (n=25, 2–3 sessions/week), committed exercisers (n=25, 4–5 sessions/week), and competitive Masters Athletes (n=25, 6–7 sessions/week). The dynamic Starling mechanism was estimated by transfer function gain between beat-by-beat changes in diastolic pulmonary artery pressure, a surrogate for left ventricular end-diastolic pressure, and stroke volume index. Results: The transfer function gain of pulmonary artery pressure–stroke volume index was markedly enhanced in committed and competitive exercisers compared with more sedentary seniors and correlated with higher peak oxygen uptake (V o 2 ) and lower left ventricular stiffness. The power spectral density of pulmonary artery pressure was greater in sedentary adults than in committed and competitive exercisers, whereas the power spectral density of stroke volume index was greater in competitive exercisers than in the other groups. Conclusions: There is a graded, dose-dependent improvement in ventricular-arterial coupling with increasing amounts of lifelong regular exercise in healthy older individuals. Our data suggest that the optimal dose of lifelong endurance exercise to preserve ventricular-arterial coupling with age appears to be at least 4 to 5 sessions per week.
Baseline (BL) covariates of response to darbepoetin alfa (DA) every 2 weeks (Q2W) in patients (pts) with chemotherapy-induced anemia (CIA)
Authors: S. Vadhan-Raj, B. Mirtsching, S. A. Gregory, J. Hong, M. Fessen, B. Yao, G. Rossi, D. Blayney
Journal: Journal of Clinical Oncology (2004)

8061 Background: Classification and regression tree (CART) and multiple regression (MR) methods can be used to model BL characteristics of pts treated with DA (Aranesp®) relative to their performance on hematologic and clinical endpoints. Methods: Data from an open-label, multicenter study (SOAR) of DA 3.0 mcg/kg Q2W dosed to week (wk) 15 in pts with CIA were used in this exploratory analysis. Endpoints included % transfused from wks 5 -17, hemoglobin (Hb) change at wk 17, and ≥ 3 point FACT-Fatigue change (clinically meaningful improvement) at wk 17. MR models allow for assessment of a covariate after adjusting for the effects of other important covariates. Relative to MR, CART is more flexible in handling missing data and in discovering interactions among covariates. Results: This analysis includes data from all 1558 pts enrolled. Overall, using intent-to-treat methods, the mean (95% CL) change in Hb (n = 1462) was 1.7 (1.6, 1.8) g/dL with over 70% of pts achieving a hematopoietic response (Hb ≥ 12 g/dL or ≥ 2 g/dL rise from BL). The Kaplan-Meier % (95% CL) of pts transfused was 19% (17, 21) overall. Mean (95% CL) change in FACT-Fatigue score was 4.7 (4.1, 5.3). Statistically significant covariates by MR are shown (table). The more anemic pts were at BL, the more likely a higher Hb change would occur; the more fatigued pts were at BL, the more likely a 3-point change in FACT-Fatigue would occur. Breast and lymphoid cancer pts responded well relative to lung cancer pts, although this may be related to factors such as gender, chemotherapy, and disease stage. Ferritin and serum erythropoietin levels (after adjusting for tumor type and BL Hb or FACT-Fatigue) were also significant but less impactful covariates. Conclusions: Response to erythropoietic therapy in pts with CIA is significantly impacted by BL Hb category and tumor type. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Amgen, Inc. Amgen, Inc. Amgen, Inc. Amgen, Inc. Amgen, Inc.